PROF — Profound Medical Corp.

Summary of Profound Medical (PROF) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Q4 2025 revenue reached $6 million, a 43% increase from $4.2 million in Q4 2024. This included $2.3 million from recurring revenue and $3.7 million from capital equipment sales.
• Gross Margin: Gross margin was 67%, down from 71% in Q4 2024, attributed to product mix and introductory pricing in new international markets.
• Operating Expenses: Total operating expenses were $11.4 million, slightly up from $11.3 million in Q4 2024.
• Net Loss: The net loss for Q4 2025 was $8.2 million ($0.27 per share), compared to a loss of $4.9 million ($0.20 per share) in Q4 2024.
• Cash Position: As of December 31, 2025, cash reserves stood at $59.7 million.

2. Strategic Updates and Business Highlights

• Clinical Developments: The CAPTAIN trial, a key study comparing TULSA technology to robotic prostatectomy, completed recruitment and is set to present preliminary results at the European Association of Urology meeting. This trial is expected to solidify TULSA's position in prostate cancer treatment.
• Market Expansion: The company has signed distribution agreements in Saudi Arabia and Australia, with initial sales reported.
• Sales Pipeline: The TULSA-PRO sales pipeline includes 110 new systems in various stages of negotiation, indicating strong commercial momentum.
• Reimbursement Progress: TULSA procedure reimbursement has been confirmed for 2026, with ongoing engagement with private insurers expected to yield coverage decisions in the latter half of 2026.

3. Forward Guidance and Outlook

• Revenue Growth: The company anticipates high double-digit to low triple-digit revenue growth in 2026, driven by increased site installations and utilization.
• Cash Flow Positivity: Profound aims to achieve cash flow positivity with projected revenues of $80 million to $85 million, with a declining cash burn trend observed in recent quarters.

4. Bad News, Challenges, or Points of Concern

• Declining Gross Margin: The decrease in gross margin raises concerns about pricing strategies and product mix, particularly in new markets.
• Net Loss Increase: The widening net loss could impact investor sentiment and raises questions about the sustainability of current spending levels.
• Utilization Rates: Current utilization rates per site are below expectations, with many new installations not yet contributing significantly to revenue. The company needs to enhance site engagement to drive higher procedure volumes.
• Competitive Landscape: The ongoing competition from other prostate cancer treatment modalities, particularly robotic surgery and focal therapies, presents a risk to market share.

5. Notable Q&A Insights

• Private Payer Reimbursements: The company reported successful coverage reversals from private insurers, with most reimbursements ranging from 1.5x to 2.5x Medicare rates.
• Utilization Dynamics: There was a noted decline in non-capital revenue sequentially, with management attributing this to the early stages of site adoption and capital-heavy sales mix.
• Future Installations: Management indicated that they are addressing logistics and operational bottlenecks to support the anticipated increase in installations throughout 2026.
• BPH Module Adoption: Ten sites are currently using the new BPH module, with expectations for rapid growth in adoption as the year progresses.

Overall, while Profound Medical shows promising growth potential and strategic advancements, it faces challenges in margin compression, increasing losses, and the need for improved utilization rates at newly installed sites.